Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Early Meetings Aid First-Cycle Approval If Sponsors Act, Consultants Tell FDA

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

NDA and BLA sponsors contribute to the need for multi-cycle reviews by failing to act on FDA recommendations made during development "milestone" meetings, according to an independent analysis of the agency’s first-cycle review performance.

You may also be interested in...

Priority Review's Luster Dims In "Safety First Era" But Retains Value - Parexel

Sponsors of the most innovative new drugs should not be deterred by the apparent reversals of fortune in the last year for NDAs with priority review status, the consulting firm Parexel concludes in a new report.

FDA First-Cycle Approval Rate For NMEs Leaps To 50% In 2003

FDA’s efforts to increase first-cycle approvals appear to be paying off, with the agency showing a significant improvement in 2003 compared to 2002.

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts